The continuous glucose monitoring market, introduced nearly 20 years ago, is presently experiencing strong growth as diabetics, physicians, hospitals and clinics witness the benefits these devices can lend to the management of glucose levels. The market now includes blood glucose monitors, diabetes test strips, insulin durable and patch pumps, glucose sensors, and transmitters and receivers. The global market for continuous glucose monitoring equipment is expected to top $20.6 billion by 2022, according to a new study by BCC Research, at a five-year compound annual growth rate (CAGR) of 10.1%.
Earlier this month, BCC Research hosted an event “Connected Medical Devices: Bridging the Gap Between Wearables and Clinical Applications” in Boston, MA. BCC Research Senior editors Michael Sullivan and Robert G. Hunter discussed the future of wearable medical devices, especially those that link clinical and consumer applications. In her blog post from August 2017, Laurie Sullivan writes about one Google spin-off coming ever closer to “bridging the gap.”
There has been increasing interest in botanical drugs, with many players investigating their commercial potential. According to BCC Research, the global market for plant-derived and botanical drugs is expected to reach $39.6 billion by 2022. Excluding botanicals, growth in the plant-derived drug market is in line with the overall pharmaceutical industry, given the presence of generics (including biosimilars). Patent expirations will necessitate medicinal compounds other than single chemical entities. Growth in the U.S. market for plant-derived drugs will reflect new cannabinoids and their overall expanded uses, as well as eventual brand line extensions.
Ahead of the January 2018 update on the report “3D Cell Cultures: Technologies and Global Markets,” we are resharing Laurie Sullivan’s blog from July. On January 24, 2018, the analyst Robert G. Hunter will present a Member Exclusive Webinar and Q&A session on this report. Purchase the report or become a Member to attend!